One injection instead of two. That is now the most efficient way to protect girls against cervical cancer, according to the World Health Organization's top vaccine advisers — a shift that could decide whether the world meets its goal of eliminating the disease within a generation.
On October 13, 2026, the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) concluded, after reviewing updated evidence, that a single dose of HPV vaccine for girls aged 9 to 14 is now "the most efficient approach" to reaching global immunization targets. It is a striking escalation from 2022, when SAGE described the single dose merely as an acceptable alternative schedule.
The announcement came with another headline: countries should consider routinely vaccinating girls as young as 4 to 8 — provided doing so would lift vaccine coverage. With global HPV coverage stalled at 33 percent against a 90 percent target, the world's immunization experts want the shot in more arms, faster.
Why This Matters: The Cervical Cancer Crisis
Cervical cancer is a paradox: it is one of the most preventable cancers in the world, yet it kills hundreds of thousands of women every year. Persistent HPV infection causes virtually every case — more than 95 percent — and the disease remains the fifth most commonly diagnosed cancer in women worldwide.
The latest WHO figures are sobering. In 2024, there were around 604,000 new cases of cervical cancer and about 280,000 deaths. The burden is brutally unequal: 94 percent of those deaths occurred in low- and middle-income countries, where vaccination, screening, and treatment are hardest to reach.
This is also a cancer unlike most others. Vaccination, according to the WHO, prevents 90 percent of these cancers from developing. Few diseases offer such a clean equation: vaccinate a generation of girls, and a cancer that has shadowed women for millennia begins to disappear — the same prevention-first principle behind our investigation into how ultra-processed foods raise colon cancer risk.
What the WHO's Vaccine Experts Actually Said
SAGE chair Anthony Scott told reporters in Geneva that some 165 countries have now introduced the HPV vaccine. The problem is not the science; it is the reach. "However, the global HPV vaccine coverage, at 33%, is far short of the global target we're looking for, which is 90%," he said.
That 90 percent target comes from the WHO's global cervical cancer elimination strategy, adopted by all 194 member states in 2020. Its 2030 targets — 90 percent of girls vaccinated by 15, 70 percent of women screened twice, 90 percent of those found with disease treated — are the roadmap to making cervical cancer the first cancer ever eliminated as a public health problem.
Here is what SAGE recommended this month:
Girls aged 9 to 14 remain the priority group. For them, a single dose is now the recommended, most efficient schedule — not an alternative, the default strategy.
Girls aged 4 to 8 may be vaccinated too. SAGE said countries "may also consider routine vaccination for girls aged four to eight" if it would lift coverage — for example by folding it into childhood immunization visits where attendance is highest.
The single dose can extend outward in a strict priority order. Catch-up of women up to 25 comes first, then women up to 30, then routine vaccination of boys aged 9 to 14, and finally catch-up of males up to 20. Exceptions stay: immunocompromised people, including those with well-controlled HIV, still need two doses; the severely immunocompromised need three.
Compare this with the 2022 guidance: back then, SAGE recommended one or two doses for girls 9 to 14, the same for young women 15 to 20, and two doses six months apart for women over 21. The single dose was tolerated as an option. Now it is the plan.
The Vaccines Behind the Shot
The HPV vaccine is not one product. As of 2025, there are eight licensed HPV vaccines worldwide, and the WHO has prequalified five products for use in national immunization programs: three bivalent vaccines (Cervarix, Cecolin, Walrinvax — types 16 and 18), one quadrivalent (Gardasil — types 6, 11, 16, 18), and one nonavalent (Gardasil 9 — nine types). India's Cervavac is licensed nationally as a quadrivalent option.
The WHO confirms single-dose use is appropriate for Cecolin, Cervarix, Gardasil, and Gardasil 9 — the vaccines with the strongest single-dose evidence. Types 16 and 18 cause about 77 percent of cervical cancers, while types 31, 33, 45, 52, and 58 account for nearly 18 percent more; the nonavalent Gardasil 9, standard in countries like the United States and Australia, covers all nine.
The schedule has been shrinking for years: three doses when the first vaccine launched in 2006, two for younger adolescents from 2013, and now one for the core 9-to-14 group — a two-decade march toward the simplest possible protection.
Cheaper options matter: Cecolin costs roughly 55 to 65 percent less per dose than Gardasil or Cervarix in the Gavi program, and WHO prequalification of the lower-cost bivalent vaccines opens the door to affordable single-dose rollouts. Where price decides who gets protected, that changes the arithmetic.
Why One Shot Changes Everything
Halving the number of doses does not halve the impact — it multiplies the reach. Every second dose that does not need to be scheduled, transported, refrigerated, and administered is a second dose that can go to another child.
A two-dose schedule demands two clinic visits months apart, tracking who missed dose two, and twice the refrigerated stock. In remote districts with one nurse and a motorbike, the second visit is where programs go to die.
A single dose collapses all of that into one contact: one school visit can cover an entire class, and countries can stretch limited supply across twice as many people. It also arrives as health budgets tighten — the WHO framed this month's recommendations explicitly as ways to help resource-constrained countries do more with less.
The scale of the gap shows why. By the end of 2025, more than 95 million girls had received HPV vaccines, according to Kate O'Brien, head of the WHO's vaccines department. That sounds enormous — until set against the 90-percent-by-age-15 target for every girl on Earth. Moving from 33 to 90 percent coverage is the entire ballgame, and SAGE has now declared that the single dose is the most efficient way to get there.
The evidence behind early, wide vaccination is striking. A landmark 2020 New England Journal of Medicine study of 1.7 million Swedish women found vaccination cut invasive cervical cancer risk by 63 percent overall — 88 percent when given before age 17. A Scottish study found zero cases of invasive cervical cancer among girls vaccinated at age 12 to 13, and a 2026 English study reported zero cervical cancer deaths among vaccinated 20-to-24-year-olds, against 23 expected from historical rates. Vaccinate early and widely, and the cancer all but vanishes.
[ |
What Two Decades of Safety Data Tell Us
No vaccine enters wider use under more scrutiny than one given to healthy children — and the HPV vaccine now has nearly twenty years of it. The vaccine has been in use since 2006 and has been given to more than 270 million people worldwide.
The WHO's Global Advisory Committee on Vaccine Safety has monitored hundreds of millions of administered doses across the 165 countries that have integrated HPV vaccination into national programs. Its updated assessments confirm that severe adverse reactions remain exceedingly rare. Notably, the most commonly reported event among adolescents is fainting — recognized as an anxiety-related response to needles themselves, not a reaction to the vaccine.
Common side effects are mild: soreness at the injection site, mild fever in roughly 4 percent of recipients, and headache or fatigue resolving within a day or two. Multiple large studies have found no link between the HPV vaccine and infertility, autoimmune conditions, or chronic illness — persistent online claims to the contrary are not supported by the evidence.
What This Means for You and Your Family
Guidance from Geneva takes time to reach your local clinic, since countries set their own schedules — but here is how to read the new landscape.
The core message is reassuring, not alarming. If your daughter received one dose under the old two-dose schedule, the evidence now says that shot is doing its job. The move to one dose reflects stronger evidence, not weaker standards.
Girls aged 9 to 14 remain the priority everywhere. This is the age group where the immune response is strongest and protection begins before any exposure to the virus. The new 4-to-8 option is a country-level decision aimed at coverage, not a requirement for individual parents.
Boys are in the picture too. HPV causes cancers in men — including anal and throat cancers — and vaccinating boys protects them directly while reducing transmission. Routine vaccination of boys aged 9 to 14 sits in SAGE's expansion order, and many countries already vaccinate both sexes.
Vaccination does not end the need for screening. The vaccine covers the types behind the large majority of cervical cancers, but not every type — and it cannot protect anyone already exposed. Keep up cervical screening on your national schedule: the shot and screening are two halves of the same protection.
Lifestyle still matters for prevention. A strong immune system clears most HPV infections on its own within a couple of years, so supporting it through healthy habits is part of the picture. Our complete guide to healthy eating and our deep dive into the science of sleep debt both explore how everyday choices shape immune defenses.
One important note: this article is informational only and is not medical advice. Vaccine schedules, eligibility ages, and availability differ by country. If you or your child are due for vaccination, talk to your healthcare provider or local immunization program about what applies to you.
What Happens Next
SAGE advises, the WHO's Director-General decides, and countries implement. Next: national schedules update, supply chains adjust, and — the experts hope — a visible climb from 33 percent toward 90.
The prize is historic: a vaccine that prevents 90 percent of cases, tests that catch the rest early, and treatments that cure early disease. No cancer is closer to elimination. The October 2026 guidance does not change the tools. It changes the strategy for getting them into every girl on Earth — one shot at a time.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance about vaccination.
